Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.38 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.38 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | RXRG | P48443 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 4/20 | 0.31 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.31 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.31 |
| ▸ | RET | P07949 | 2/20 | 0.30 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23546535 | 0.91 | RXRA (0.36) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL23043733 | 0.89 | CYP4F2 (0.39) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL29937228 | 0.89 | CYP4F2 (0.37) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL24803541 | 0.89 | CYP4F2 (0.37) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL25795327 | 0.88 | RXRA (0.40) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL21243898 | 0.88 | CYP4F2 (0.36) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL29418904 | 0.88 | CYP4F2 (0.36) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL24536354 | 0.87 | CYP4F2 (0.37) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL29680540 | 0.87 | CYP4F2 (0.37) | CYP4F2CYP4A11RXRARXRBRXRG | |
| SCHEMBL30922732 | 0.86 | RXRA (0.34) | CYP4F2CYP4A11RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | Mirati Therapeutics, Inc. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4735439-A1 | KRAS INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| EP-4631948-A1 | NOVEL TRICYCLIC COMPOUND AS KRAS G12D INHIBITOR, AND USE THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2025-10-15 | — | — | EP | disclosed |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250263424-A1 | KRAS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-08-21 | — | — | US | disclosed |
| EP-4598921-A1 | MACROCYCLIC KRAS INHIBITORS AND METHODS OF USE | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-07-24 | — | — | US | disclosed |
| WO-2025136346-A1 | INDAZOLE CONTAINING COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2022133731-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A KRAS G12C INHIBITOR AND USES OF A KRAS G12C INHIBITOR AND FOR THE TREATMENT OF CANCERS | NOVARTIS AG (CH) | 2022-06-30 | — | — | WO | disclosed |
| CN-114615981-A | KRAS G12D inhibitors | 米拉蒂治疗股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2022089604-A1 | NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND | NOVARTIS AG (CH) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022089604-A1 | NEW CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR COMPOUND | NOVARTIS AG (CH) | 2022-05-05 | — | — | WO | disclosed |
| WO-2022031678-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-02-10 | — | — | WO | disclosed |
| WO-2021124222-A1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021120890-A1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021041671-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2021-03-04 | — | — | WO | disclosed |
| US-10590115-B2 | Tetrahydroquinazoline derivatives useful as anticancer agents | PFIZER INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | PFIZER INC. (US) | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630566-B2 | KRas G12D inhibitors | KRAS, NRAS, HRAS | CYP4F2 3406/4885CYP4A11 1064/4885RXRA 4205/4885 |
| US-20250236631-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | CYP4F2 4059/4885CYP4A11 1348/4885RXRA 1531/4885 |
| US-20190248767-A1 | Tetrahydroquinazoline Derivatives Useful as Anticancer Agents | TOP2A, TOP1, TOP2B | CYP4F2 579/4885CYP4A11 1687/4885RXRA 4159/4885 |
| US-10590115-B2 | Tetrahydroquinazoline derivatives useful as anticancer agents | TOP2A, TOP1, TOP2B | CYP4F2 579/4885CYP4A11 1687/4885RXRA 4159/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | CYP4F2 4455/4885CYP4A11 2667/4885RXRA 3377/4885 |
| US-20250304599-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | CYP4F2 4059/4885CYP4A11 1348/4885RXRA 1531/4885 |
| US-20250263424-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | CYP4F2 4675/4885CYP4A11 4085/4885RXRA 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.